(Credit-Canva)
Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!
The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.
"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.
The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.
While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.
And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.
Credit: X
Researchers at the University of Texas at Austin have developed a soft, wearable device that targets a deep brain region involved in sleep regulation through focused ultrasound.
In a study published in Nature Communications, the patch, called NEUSLeeP, was found to boost REM sleep and help people reach that stage of restorative rest faster.
NEUSLeeP is a bioelectronic patch that can be attacked on the skin. It combines focused ultrasound stimulation with electrodes that continuously monitor brain activity during sleep.
The device targets the subthalamic nucleus (STN), a deep structure within the brain that forms part of the basal ganglia network.
Researchers used a specialised ultrasound array to focus stimulation on the region while simultaneously recording electrical signals linked to sleep.
“This is the first time we’ve been able to noninvasively target deep brain regions involved in REM sleep, while simultaneously monitoring brain activity,” said Kai Wing “Kevin” Tang, who led the research.
The patch weighs about 103 grams and is designed to remain attached during overnight sleep. Its electrodes allow researchers to track EEG, eye movements and muscle activity, helping determine which stage of sleep a person is experiencing.
Also read: Practicing Yoga Everyday Does THIS To Your Sleep Cycle
The study involved 28 participants, including 16 healthy sleepers and 12 people with some degree of insomnia symptoms.
Participants underwent two consecutive nights of sleep testing, with the first night serving as the sham condition and ultrasound stimulation delivered on the second night.
Researchers found that NEUSLeeP increased the proportion of REM sleep by about 4.6 percentage points, equivalent to roughly 16 additional minutes of REM sleep. It also reduced the time taken to enter REM sleep by approximately 43 minutes, or 24%.
Additionally, researchers did not observe significant changes in other sleep stages or overall sleep efficiency.
The team also reported changes in heart-rate variability and brain activity associated with processing emotions, suggesting that manipulating REM sleep could eventually have implications beyond sleep itself.
Also read: Narcolepsy: US FDA Approves First-Ever Pill That Targets Root Cause of Rare Sleep Disorder
REM, or rapid eye movement sleep, is the stage associated with vivid dreaming, rapid eye movements and increased brain activity.
It usually becomes longer during the later part of the night and accounts for roughly 20% to 25% of sleep in adults.
REM sleep has been linked to memory processing and emotional regulation. Research has suggested that the brain uses this stage to process emotional experiences and integrate memories.
“REM sleep is not just about dreaming. It’s about emotional reset and stress adaptation,” said Gregory Fonzo, a co-principal investigator on the project.
Poor sleep is associated with several mental and neurological consequences. Researchers believe that selectively influencing REM sleep could eventually become part of treatments for sleep disorders and conditions like chronic insomnia, depression and PTSD. However, the patch is not yet a treatment available for patients.
Although the findings seem promising, they come from a small, early-stage human study involving 26 participants.
The researchers also deliberately used a fixed order, with sham stimulation on the first night and ultrasound on the second, because they were concerned about possible carryover effects.
That means larger, longer and independent trials will be needed to determine whether increasing REM sleep actually produces meaningful improvements in health, mood or daytime functioning.
Credit: AI
Cancer drug research may undergo a significant shift as scientists are not just studying what happens to a cell after treatment, but watch the process unfold in real time.
Indian-origin biotech entrepreneur Parmita Mishra is developing a live-cell technology that combines Raman spectroscopy, photonics, microfluidics and computational biology to continuously monitor living cells without fluorescent labels or destructive sample preparation.
The approach, described by the researchers as “live-cell cinema,” aims to address a longstanding problem in drug discovery: conventional laboratory techniques often provide snapshots of cellular behaviour rather than a continuous picture of how cells respond to treatment and other changes.
Mishra said, "Biology is constantly moving, yet for decades we have largely studied it through static snapshots. If we want to understand why cancer cells change, adapt or resist therapy, we need technologies that allow us to observe living biology continuously rather than after the fact. Our mission is to give researchers that capability."
Traditional experiments require cells to be fixed, stained, lysed or otherwise destroyed before researchers analyse them. Even studies that examine multiple time points may rely on different populations of cells at each stage of the research.
A recent Drug Discovery News report highlighted research that cancer cells can move through intermediate molecular states as they develop treatment resistance, suggesting that important biological changes may occur before resistance becomes obvious.
The idea behind live-cell examination is therefore simple: if biology changes continuously, why should scientists only measure it at the end?
Also read: Lung Health After 40: Natural Changes, Warning Signs And Ways To Protect Your Lungs
Raman spectroscopy analyses how light interacts with molecules, producing chemical information without necessarily requiring dyes or labels.
Its system combines this optical technology with microfluidic chips that maintain cells under controlled conditions, including temperature, nutrients and carbon dioxide. This allows researchers to observe the same living cells as their biology changes.
Mishra said that artificial intelligence can process enormous amounts of information, but its utility in drug discovery depends on having better biological data to learn from.
Also read: Tudriqev: US FDA Approves Replimune's Skin Cancer Drug After Rejecting It Twice
By capturing biochemical changes continuously, technologies such as live-cell Raman imaging could potentially help researchers identify drug responses, toxicity or resistance earlier during preclinical testing.
Dr. Shyam Aggarwal , Chairperson, Department of Medical Oncology at Sir Ganga Ram Hospital, New Delhi said “Real-time observation technologies could help researchers better understand how cells respond to candidate drugs, monitor subtle biochemical changes earlier, and potentially identify promising therapies more efficiently during preclinical research. Understanding precision oncology with CGP comprehensive genome profiling and MRD minimal residual disease detection will help physicians improve targeted personised medicine for cancer patients. While such technologies are not themselves treatments, they may strengthen the scientific foundation on which future therapies are developed.”
For cancer research, that window could eventually help scientists understand not only whether a drug works, but how a living cancer cell changes while the drug is working.
Mishra further added "We are not trying to replace scientists or physicians—we are trying to give them a better window into living biology," "When researchers can continuously measure how cells behave instead of relying on biological 'autopsies,' they may uncover insights that were previously impossible to observe. That has implications far beyond cancer, extending into immunology, neuroscience, rare diseases and regenerative medicine. "For decades, we've been studying life after it has stopped.The future of biomedical research lies in understanding life while it is still unfolding."
However, the technology is still being developed and requires independent validation before its potential impact on drug discovery can be established.
Dr Rahul Bhargava, Principal Director of Hematology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram said “Cancer is an extraordinarily dynamic disease, and researchers around the world are exploring technologies that can better capture how living cells change over time. Innovations that enable continuous, non-invasive observation of cellular behavior could become valuable research tools for improving disease models and accelerating drug discovery. While clinical validation remains essential, this represents an exciting direction for biomedical science."
Credit: X
90s star Samuel Monroe Jr., best known for his role in the 1993 film Menace II Society, remains critically ill in a Los Angeles hospital. His family is now facing the possibility that he may end up in a vegetative state.
According to the latest update shared by his wife, Shawna Stewart, Monroe is in a medically induced coma and remains on life support.
Doctors have said that he could ultimately be left in that life state as complications in his brain continue to worsen.
Samuel's health crisis reportedly began with meningitis. Stewart previously said he contracted the infection while filming in Las Vegas around 18 months before his hospitalization, but the illness was repeatedly misdiagnosed.
“Because of this negligence, the meningitis went untreated for eight months,” Stewart said. She also said that by the time it was diagnosed, the infection had spread to his spine and brain.
His condition later became more complicated after he developed MRSA pneumonia, a serious infection caused by methicillin-resistant Staphylococcus aureus. He needed life support, dialysis, and multiple blood transfusions for several months.
There was some improvement in his health in May. His kidney function improved enough for doctors to stop dialysis; he was taken off blood-pressure medication and was able to breathe without a ventilator for about four hours.
He was also reportedly alert and well enough to answer questions by moving his head. But that phase did not last.
Also read: Alex Hughes: Former Manchester United Star’s Son Dies of Sudden Adult Death Syndrome
A vegetative state is different from a coma, although both involve severe impairment of consciousness.
A person in a vegetative state may have periods of wakefulness, like opening their eyes, but may not show any sign of awareness of themselves or their surroundings. Basic functions like breathing and sleep-wake cycles can continue.
Importantly, doctors cannot determine an individual's neurological outcome from one symptom alone. The extent and location of brain injury, neurological examinations and repeated imaging, and other assessments are considered.
Also read: Donald Trump Mulls Order Targeting Childhood Vaccines And Autism
Stewart told TMZ that Monroe’s brain continues to swell and that his brain ventricles have enlarged and are struggling to properly contain cerebral fluid. The pressure and complications in his brain have triggered seizures.
Monroe has undergone three brain surgeries, while his left lung has also partially collapsed. Doctors are continuing to perform CT scans to assess his brain activity and condition.
Brain swelling is particularly dangerous as the skull is a rigid body part. When fluid or swelling increases inside it, pressure can rise and potentially damage brain tissue.
Severe or prolonged swelling can affect consciousness, movement, communication, and other essential neurological functions.
According to reports, Monroe’s family is not making an immediate decision about his life support.
Stewart said the family has agreed to wait for three or four more CT scans before making a decision. Depending on those scans, the family may have to take the decision of withdrawing life support.
© 2024 Bennett, Coleman & Company Limited